|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Safety and Efficacy of Radiofrequency Ablation in the Management of Unresectable Bile Duct and Pancreatic Cancer: A Novel Palliation Technique显示文摘 | Paola Figueroa-Barojas Mihir R. Bakhru Nagy A. Habib Kristi Ellen Jennifer Millman Armeen Jamal-Kabani Monica Gaidhane Michel Kahaleh Jose G. de la Mora-Levy | 2013 | Journal of Oncology2013，，： | 5 |
| 2 | neuroendocrine 的罐头成像模式肝的转移预言反应 yttruim-90 radioembolotherapy?显示文摘 AIM:To evaluate the response to treatment in patients with neuroendocrine tumor liver metastases following yttrium-90 ( 90 Y) radioembolotherapy, as a function of image patterns at presentation for 90 Y radioembolotherapy. METHODS: The study cohort consisted of patients with hepatic metastatic neuroendocrine tumors treated with 90 Y at our institution during a two-year time period. Hepatic metastases were evaluated on a pretherapy study assessing relative arterial enhancement compared to liver, lesion size, necrosis of the lesion, and associated tumor burden in the liver. We used six response criteria: Response Evaluation Criteria in Solid Tumors (RECIST) size, World Health Organization (WHO) size, European Association for the Study of the Liver (EASL) necrosis guidelines, Choi size, Choi necrosis and combination of Choi size and necrosis. RESULTS: About 65 lesions in 17 patients met study criteria and formed the cohort. Statistically significant response was found for lesions < 5 cm vs those ≥5 cm with RECIST (P = 0.04), WHO (P = 0.002) and combined Choi criteria (P = 0.02). Hyperenhancing lesions demonstrated greater response only with the Choi size criteria (P = 0.04). Lesions with ≤ 50% necrosis on the pre-scan had statistically significant greater response with the Choi necrosis criteria (P = 0.01). There was no statistical significance for response comparing lesions < 2 cm vs ≥ 2 cm or in comparing the degrees of tumor burden. CONCLUSION: Based on our findings in this study, it is suggested that initial imaging findings, as listed above, are not a good predictor of response to 90 Y radioembolization. | Julia Neperud Armeen Mahvash Naveen Garg Ravi Murthy Janio Szklaruk | 2013 | World Journal of Radiology2013，5，6： | 3 |
| 3 | Kinetic Growth Rate after Portal Vein Embolization Predicts Posthepatectomy Outcomes: Toward Zero Liver-Related Mortality in Patients with Colorectal Liver Metastases and Small Future Liver Remnant显示文摘 | Junichi Shindoh Mark J. Truty Thomas A. Aloia Steven A. Curley Giuseppe Zimmitti Steven Y. Huang Armeen Mahvash Sanjay Gupta Michael J. Wallace Jean-Nicolas Vauthey | 2013 | Journal of the American College of Surgeons2013，，： | 1 |
| 4 | Safety and Efficacy of Radiofrequency Ablation in the Management of Unresectable Bile Duct and Pancreatic Cancer: A Novel Palliation Technique显示文摘 | Paola Figueroa-Barojas Mihir R. Bakhru Nagy A. Habib Kristi Ellen Jennifer Millman Armeen Jamal-Kabani Monica Gaidhane Michel Kahaleh Jose G. de la Mora-Levy | 2013 | Journal of Oncology2013，，： | 1 |
| 5 | Safety and Efficacy of Radiofrequency Ablation in the Management of Unresectable Bile Duct and Pancreatic Cancer: A Novel Palliation Technique显示文摘 | Paola Figueroa-Barojas Mihir R. Bakhru Nagy A. Habib Kristi Ellen Jennifer Millman Armeen Jamal-Kabani Monica Gaidhane Michel Kahaleh Jose G. de la Mora-Levy | 2013 | Journal of Oncology2013，，： | 1 |
| 6 | Probe-based confocal laser endomicroscopy in the pancreatic duct provides direct visualization of ductal structures and aids in clinical management显示文摘 | Michel Kahaleh Brian G. Turner Karl Bezak Reem Z. Sharaiha Savreet Sarkaria Michael Lieberman Armeen Jamal-Kabani Jennifer E. Millman Subha V. Sundararajan Ching Chan Shivani Mehta Jessica L. Widmer Monica Gaidhane Marc Giovannini | 2014 | Digestive and Liver Disease2014，，： | 1 |
| 7 | Analysis of the Efficacy of Portal Vein Embolization for Patients with Extensive Liver Malignancy and Very Low Future Liver Remnant Volume, Including a Comparison with the Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy Approa显示文摘 | Junichi Shindoh Jean-Nicolas Vauthey Giuzeppe Zimmitti Steven A. Curley Steven Y. Huang Armeen Mahvash Sanjay Gupta Michael J. Wallace Thomas A. Aloia | 2013 | Journal of the American College of Surgeons2013，，1： | 1 |
| 8 | Su1612 Photodynamic Therapy in Unresectable Cholangiocarcinoma: Nine Years American Experience显示文摘 | Michel Kahaleh Amrita Sethi Michael D. Saunders Jayant P. Talreja Armeen Jamal-Kabani Monica Gaidhane David E. Loren | 2014 | Gastrointestinal Endoscopy2014，，： | 1 |
| 9 | Analysis of the Efficacy of Portal Vein Embolization for Patients with Extensive Liver Malignancy and Very Low Future Liver Remnant Volume, Including a Comparison with the Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy Approa显示文摘 | Junichi Shindoh Jean-Nicolas Vauthey Giuzeppe Zimmitti Steven A. Curley Steven Y. Huang Armeen Mahvash Sanjay Gupta Michael J. Wallace Thomas A. Aloia | 2013 | Journal of the American College of Surgeons2013，，1： | 1 |
| 10 | Kinetic Growth Rate after Portal Vein Embolization Predicts Posthepatectomy Outcomes: Toward Zero Liver-Related Mortality in Patients with Colorectal Liver Metastases and Small Future Liver Remnant显示文摘 | Junichi Shindoh Mark J. Truty Thomas A. Aloia Steven A. Curley Giuseppe Zimmitti Steven Y. Huang Armeen Mahvash Sanjay Gupta Michael J. Wallace Jean-Nicolas Vauthey | 2013 | Journal of the American College of Surgeons2013，，： | 1 |
| 11 | Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib显示文摘BACKGROUND Impressive survival outcome of our previous study in unresectable hepatocellular carcinoma(HCC)patients undergoing yttrium-90 glass microspheres transarterial radioembolization(TARE)with/without sorafenib according to individuals’disease burden,i.e.,intrahepatic tumor load(IHT)and adverse disease features(ADFs)might partly be confounded by other treatments and underlying hepatic function.Therefore,a dedicated study focusing on treatment response and assessment of failure patterns might be a way to improve treatment outcome in addition to patient selection based on the disease burden.AIM To assess the tumor response,disease control and patterns of disease progression following TARE with/without sorafenib in unresectable HCC patients.METHODS This retrospective study was conducted in successful TARE procedures with available pre-and post-treatment imaging studies(n=169).Three treatment subgroups were(1)TARE only(TARE_alone)for IHT≤50%without ADFs,i.e.,macrovascular invasion,extrahepatic disease(EHD)and infiltrative/ill-defined HCC(n=63);(2)TARE with sorafenib(TARE_sorafenib)for IHT>50%and/or presence of ADFs(n=81);and(3)TARE only for patients who could not receive sorafenib due to contraindication or intolerance(TARE_no_sorafenib)(n=25).Objective response rate(ORR;consisted of complete response(CR)and partial response(PR)),disease control rate(DCR;consisted of CR,PR and stable disease)and failure patterns of treated,intrahepatic and extrahepatic sites were assessed using the modified response evaluation criteria in solid tumors.Time to progression(TTP)was calculated from TARE to the first radiologic progression at any site using Kaplan-Meier method.Identification of prognostic factors for TTP using the univariate Kaplan-Meier method and multivariate Cox proportional hazard model were performed in major population subgroups,TARE_alone and TARE_sorafenib.RESULTS The median radiologic follow-up time was 4.4 mo(range 0.5-48.8).In treated area,ORR was highest in TARE_sorafenib(53.1%),followed by TARE_alone(41.3%)and TARE_no_sorafenib(16%).In intrahepatic area,DCR remained highest in TARE_sorafenib(84%),followed by TARE_alone(79.4%)and TARE_no_sorafenib(44%).The overall DCR was highest in TARE_alone(79.4%),followed by TARE_sorafenib(71.6%)and TARE_no_sorafenib(40%).Dominant failure patterns were intrahepatic for both TARE_alone(44.5%)and TARE_sorafenib(38.4%).Extrahepatic progression was more common in TARE_sorafenib(32%)and TARE_no_sorafenib(40%)than in TARE_alone(12.7%).TTP was longest in TARE_alone(8.6 mo;95%CI:3.4-13.8),followed by TARE_sorafenib(5.1 mo;95%CI:4.0-6.2)and TARE_no_sorafenib(2.7 mo;95%CI:2.2-3.1).Pre-existing EHD(HR:0.37,95%CI:0.24-0.56,P<0.001)was a sole prognostic factor for TTP in TARE_sorafenib with no prognostic factor for TTP in TARE_alone.CONCLUSION TARE with/without sorafenib according to individuals’disease burden provided DCR approximately 70%with intrahepatic progression as dominant failure pattern.Extrahepatic progression was more common in procedures with initially high disease burden. | Ajalaya Teyateeti Armeen Mahvash James Long Mohamed Abdelsalam Rony Avritscher Ahmed Kaseb Bruno Odisio Gregory Ravizzini Devaki Surasi Achiraya Teyateeti Homer Macapinlac Srinivas Cheenu Kappadath | 2021 | World Journal of Gastroenterology2021，27，47： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员